See more : Tessin Nordic Holding AB (publ) (TESSIN.ST) Income Statement Analysis – Financial Results
Complete financial analysis of ZimVie Inc. (ZIMV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZimVie Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Lanebury Growth Capital Ltd. (LLL.CN) Income Statement Analysis – Financial Results
- 3D Oil Limited (TDO.AX) Income Statement Analysis – Financial Results
- Aoshikang Technology Co., Ltd. (002913.SZ) Income Statement Analysis – Financial Results
- Hermès International Société en commandite par actions (HESAY) Income Statement Analysis – Financial Results
- Jewett-Cameron Trading Company Ltd. (JCTCF) Income Statement Analysis – Financial Results
ZimVie Inc. (ZIMV)
About ZimVie Inc.
ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 457.43M | 913.86M | 1.01B | 912.40M | 1.06B | 1.10B |
| Cost of Revenue | 167.05M | 300.79M | 385.80M | 312.90M | 333.90M | 382.70M |
| Gross Profit | 290.38M | 613.08M | 628.80M | 599.50M | 721.60M | 716.40M |
| Gross Profit Ratio | 63.48% | 67.09% | 61.98% | 65.71% | 68.37% | 65.18% |
| Research & Development | 26.16M | 62.69M | 61.30M | 49.20M | 55.60M | 52.30M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 248.96M | 523.97M | 554.40M | 533.50M | 605.40M | 599.90M |
| Other Expenses | 46.20M | 80.87M | 86.20M | 85.50M | 83.40M | -600.00K |
| Operating Expenses | 321.32M | 667.53M | 701.90M | 668.20M | 744.40M | 747.40M |
| Cost & Expenses | 488.37M | 968.31M | 1.09B | 981.10M | 1.08B | 1.13B |
| Interest Income | 0.00 | 18.28M | 292.00K | 302.00K | 100.00K | 0.00 |
| Interest Expense | 20.23M | 18.28M | 300.00K | 300.00K | 100.00K | 100.00K |
| Depreciation & Amortization | 121.69M | 122.79M | 129.70M | 134.30M | 135.10M | 147.70M |
| EBITDA | 91.07M | 79.16M | 28.70M | -86.70M | 107.50M | -326.40M |
| EBITDA Ratio | 19.91% | 7.87% | 5.53% | 7.37% | 10.66% | 10.56% |
| Operating Income | -30.94M | -50.85M | -73.60M | -67.10M | -22.60M | -473.50M |
| Operating Income Ratio | -6.76% | -5.56% | -7.25% | -7.35% | -2.14% | -43.08% |
| Total Other Income/Expenses | -19.91M | -8.01M | -123.12M | 1.31M | 100.00K | -700.00K |
| Income Before Tax | -50.85M | -109.92M | -101.30M | -221.30M | -27.70M | -474.20M |
| Income Before Tax Ratio | -11.12% | -12.03% | -9.98% | -24.25% | -2.62% | -43.14% |
| Income Tax Expense | 5.20M | -46.04M | -6.00M | -42.30M | 200.00K | -14.80M |
| Net Income | -393.28M | -63.88M | -95.30M | -179.00M | -27.90M | -460.40M |
| Net Income Ratio | -85.98% | -6.99% | -9.39% | -19.62% | -2.64% | -41.89% |
| EPS | -14.87 | -2.45 | -3.65 | -6.86 | -1.07 | -17.64 |
| EPS Diluted | -14.87 | -2.45 | -3.65 | -6.86 | -1.07 | -17.64 |
| Weighted Avg Shares Out | 26.45M | 26.08M | 26.10M | 26.10M | 26.10M | 26.10M |
| Weighted Avg Shares Out (Dil) | 26.45M | 26.08M | 26.10M | 26.10M | 26.10M | 26.10M |
ZimVie to Report Third Quarter 2023 Financial Results on November 1, 2023
ZimVie Announces the Recent Launch of Biotivity™ A/C Plus Membrane
ZimVie Announces FDA Approval to Launch Mobi-C® Hybrid Study
ZimVie Expands Development Cooperation Agreement with Brainlab AG to Include Co-Marketing
Why Fast-paced Mover ZimVie Inc. (ZIMV) Is a Great Choice for Value Investors
ZimVie Inc. (ZIMV) Q2 2023 Earnings Call Transcript
ZimVie Inc. (ZIMV) Tops Q2 Earnings and Revenue Estimates
ZimVie Reports Second Quarter 2023 Financial Results and Provides Update to Annual Guidance
ZimVie Inc. (ZIMV) Stock Jumps 20.6%: Will It Continue to Soar?
ZimVie to Report Second Quarter 2023 Financial Results on August 2, 2023
Source: https://incomestatements.info
Category: Stock Reports